Search

Your search keyword '"Kohler CG"' showing total 85 results

Search Constraints

Start Over You searched for: Author "Kohler CG" Remove constraint Author: "Kohler CG"
85 results on '"Kohler CG"'

Search Results

1. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis

2. Impairment in emotion recognition abilities in patients with mild cognitive impairment, early and moderate Alzheimer disease compared with healthy comparison subjects.

4. Review: the case for antidepressants for treating depression in people with schizophrenia remains unproven.

5. Tobacco smoking and nicotine vaping in persons with first episode psychosis.

6. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis.

7. Implementation of an Adapted Fidelity Scale for Pennsylvania Coordinated Specialty Care Programs for First Episode Psychosis.

8. The Ethics of Risk Prediction for Psychosis and Suicide Attempt in Youth Mental Health.

9. Evaluation of a new intrinsic and extrinsic motivation scale in youth with psychosis spectrum symptoms.

10. COVID-19 Impacts on Pennsylvania Coordinated Specialty Care for Early Psychosis Participants.

11. Tele-mental Health Transitions for Pennsylvania Coordinated Specialty Care Programs for Early Psychosis During the COVID-19 Pandemic.

12. Telehealth of Coordinated Specialty Care in Early Psychosis During COVID-19.

13. A systematic review and meta-analysis of intellectual, neuropsychological, and psychoeducational functioning in neurofibromatosis type 1.

14. Feasibility of Mobile Health and Social Media-Based Interventions for Young Adults With Early Psychosis and Clinical Risk for Psychosis: Survey Study.

15. Illness Phase as a Key Assessment and Intervention Window for Psychosis.

16. Pennsylvania coordinated specialty care programs for first-episode psychosis: 6- and 12-month outcomes.

17. Few primary care pediatricians screen for psychosis but many are willing.

18. Theatre improvisation training to promote social cognition: A novel recovery-oriented intervention for youths at clinical risk for psychosis.

19. Meta-analysis of olfactory dysfunction in 22q11.2 deletion syndrome.

20. Reduced safety processing during aversive social conditioning in psychosis and clinical risk.

21. Comparing Patient, Clinician, and Caregiver Perceptions of Care for Early Psychosis: A Free Listing Study.

22. The Psychosis Spectrum in 22q11.2 Deletion Syndrome Is Comparable to That of Nondeleted Youths.

23. Persistence of psychosis spectrum symptoms in the Philadelphia Neurodevelopmental Cohort: a prospective two-year follow-up.

24. Impact of psychiatric comorbidity and cognitive deficit on function in 22q11.2 deletion syndrome.

25. Lexical use in emotional autobiographical narratives of persons with schizophrenia and healthy controls.

26. Subthreshold psychotic symptoms in 22q11.2 deletion syndrome.

27. Facial emotion perception differs in young persons at genetic and clinical high-risk for psychosis.

28. Olfactory processing in schizophrenia, non-ill first-degree family members, and young people at-risk for psychosis.

29. Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated.

30. Misperceptions of facial emotions among youth aged 9-14 years who present multiple antecedents of schizophrenia.

31. Dimensional information-theoretic measurement of facial emotion expressions in schizophrenia.

32. Meta-analysis of olfactory function in schizophrenia, first-degree family members, and youths at-risk for psychosis.

33. The effect of odor valence on olfactory performance in schizophrenia patients, unaffected relatives and at-risk youth.

34. Odor hedonic capacity and anhedonia in schizophrenia and unaffected first-degree relatives of schizophrenia patients.

35. Facial emotion recognition in adolescents with psychotic-like experiences: a school-based sample from the general population.

36. Qualitatively distinct factors contribute to elevated rates of paranoia in autism and schizophrenia.

37. An odor-specific threshold deficit implicates abnormal cAMP signaling in youths at clinical risk for psychosis.

38. Automated Facial Action Coding System for dynamic analysis of facial expressions in neuropsychiatric disorders.

39. Facial emotion perception in depression and bipolar disorder: a quantitative review.

40. Ventrolateral prefrontal cortex and the effects of task demand context on facial affect appraisal in schizophrenia.

41. Psychiatric manifestations of paraneoplastic disorders.

42. Facial emotion perception in schizophrenia: a meta-analytic review.

43. Do we recognize facial expressions of emotions from persons with schizophrenia?

44. Association of enhanced limbic response to threat with decreased cortical facial recognition memory response in schizophrenia.

45. Profile of auditory information-processing deficits in schizophrenia.

46. Dynamic evoked facial expressions of emotions in schizophrenia.

47. Static posed and evoked facial expressions of emotions in schizophrenia.

48. Abnormal superior temporal connectivity during fear perception in schizophrenia.

49. Olfactory physiological impairment in first-degree relatives of schizophrenia patients.

50. Effect of retrieval effort and switching demand on fMRI activation during semantic word generation in schizophrenia.

Catalog

Books, media, physical & digital resources